Recursion Pharmaceuticals Inc (RXRX)
6.82
+0.20
(+3.02%)
USD |
NASDAQ |
Nov 05, 16:00
6.83
+0.01
(+0.15%)
After-Hours: 20:00
Recursion Pharmaceuticals Research and Development Expense (Annual): 241.23M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 241.23M |
| December 31, 2022 | 155.70M |
| December 31, 2021 | 135.27M |
| Date | Value |
|---|---|
| December 31, 2020 | 63.32M |
| December 31, 2019 | 45.81M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
45.81M
Minimum
2019
241.23M
Maximum
2023
128.26M
Average
135.27M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Eli Lilly and Co | 9.313B |
| Pfizer Inc | 10.68B |
| Revance Therapeutics Inc | 79.41M |
| Twist Bioscience Corp | 106.89M |
| NovaBay Pharmaceuticals Inc | 0.068M |